An Analysis of the SALT 1 and SALT 2 Studies
Frederick Alan Rapoport, MD, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia
Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia.
Clinical Pearls:
- The SALT 1 and SALT 2 studies, which looked at the efficacy of tolvaptan (Samsca), found that there was a statically significant improvement in patients’ serum sodium levels compared to placebo after 30 days
- Most improvement occurred within the first 4 days
- Patients should be monitored in a hospital for the first four days and remain closely monitored after that to ensure that there is not an overcorrection of the serum sodium levels.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
